

University of Groningen

## Metabolic risk in people with psychotic disorders

Bruins, Jojanneke

**IMPORTANT NOTE:** You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

*Document Version*

Publisher's PDF, also known as Version of record

*Publication date:*

2016

[Link to publication in University of Groningen/UMCG research database](#)

*Citation for published version (APA):*

Bruins, J. (2016). *Metabolic risk in people with psychotic disorders: No mental health without physical health*. [Thesis fully internal (DIV), University of Groningen]. Rijksuniversiteit Groningen.

### Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).


The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.

### Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

# References



1. Allardyce J, McCreadie RG, Morrison G, van Os J. Do symptom dimensions or categorical diagnoses best discriminate between known risk factors for psychosis? *Social Psychiatry and Psychiatric Epidemiology*. 2007;42(6):429-437.
2. McCleery A, Ventura J, Kern RS, et al. Cognitive functioning in first-episode schizophrenia: MATRICS consensus cognitive battery (MCCB) profile of impairment. *Schizophr Res*. 2014;157(1-3):33-39.
3. Wilk CM, Gold JM, McMahon RP, Humber K, Iannone VN, Buchanan RW. No, it is not possible to be schizophrenic yet neuropsychologically normal. *Neuropsychology*. 2005;19(6):778-786.
4. Patel R, Jayatilleke N, Jackson R, Stewart R, McGuire P. Investigation of negative symptoms in schizophrenia with a machine learning text-mining approach. *The Lancet*. 2014;383:S16.
5. Tsapakis EM, Dimopoulou T, Tarazi FI. Clinical management of negative symptoms of schizophrenia: An update. *Pharmacol Ther*. 2015;153:135-147.
6. Bobes J, Arango C, Garcia-Garcia M, Rojas J, CLAMORS Study Collaborative Group. Prevalence of negative symptoms in outpatients with schizophrenia spectrum disorders treated with antipsychotics in routine clinical practice: Findings from the CLAMORS study. *Journal of Clinical Psychiatry*. 2010;71(3):280-286.
7. De Hert M, Schreurs V, Vancampfort D, Van Winkel R. Metabolic syndrome in people with schizophrenia: A review. *World Psychiatry*. 2009;8(1):15-22.
8. Fleischhacker WW, Cetkovich-Bakmas M, De Hert M, et al. Comorbid somatic illnesses in patients with severe mental disorders: Clinical, policy, and research challenges. *Journal of Clinical Psychiatry*. 2008;69(4):514-519.
9. De Hert M, Correll CU, Bobes J, et al. Physical illness in patients with severe mental disorders. I. prevalence, impact of medications and disparities in health care. *World Psychiatry*. 2011;10(1):52-77.
10. Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risk of cardiovascular disease. *American Heart Journal*. 2005;150:1115-1121.
11. Ratliff JC, Palmese LB, Reutenauer EL, Srihari VH, Tek C. Obese schizophrenia spectrum patients have significantly higher 10-year general cardiovascular risk and vascular ages than obese individuals without severe mental illness. *Psychosomatics: Journal of Consultation Liaison Psychiatry*. 2013;54(1):67-73.
12. Ringen PA, Engh JA, Birkenaes AB, Dieset I, Andreassen OA. Increased mortality in schizophrenia due to cardiovascular disease - A non-systematic review of epidemiology, possible causes, and interventions. *Frontiers in Psychiatry*. 2014;5:137.
13. Lalonde M, ed. *A new perspective on the health of Canadians*. Ottawa, Ontario, Canada: Minister of Supply and Services; 1974.
14. Glouberman S, Millar J. Evolution of the determinants of health, health policy, and health information systems in Canada. *Am J Public Health*. 2002;93(3):388-392.

15. Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. *Nature*. 2014;511(7510):421-427.
16. Zhu X, Deng F, Wu L, Tang Z, Lei S. Functional mechanisms for type 2 diabetes-associated genetic variants. *J Diabetes Complications*. 2015;29(4):497-501.
17. Craddock N, O'Donovan MC, Owen MJ. The genetics of schizophrenia and bipolar disorder: Dissecting psychosis. *Journal of Medical Genetics*. 2005;42(3):193-204.
18. Liu Y, Li Z, Zhang M, Deng Y, Yi Z, Shi T. Exploring the pathogenetic association between schizophrenia and type 2 diabetes mellitus diseases based on pathway analysis. *BMC Medical Genomics*. 2013;6:S17-S17.
19. Di Forti M, Iyegbe C, Sallis H, et al. Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users. *Biol Psychiatry*. 2012;72(10):811-816.
20. Devaney JM, Gordish-Dressman H, Harmon BT, et al. AKT1 polymorphisms are associated with risk factors for metabolic syndrome. *Human Genetics*. 2011;129(2):129-139.
21. Miller BJ, Culpepper N, Rapaport MH. C-reactive protein levels in schizophrenia. *Clinical Schizophrenia & Related Psychoses*. 2014;7(4):223-230.
22. Foley DL, Mackinnon A, Morgan VA, et al. Common familial risk factors for schizophrenia and diabetes mellitus. *Australian and New Zealand Journal of Psychiatry*. 2015.
23. Bobes J, Arango C, Aranda P, Carmena R, Garcia-Garcia M, Rejas J. Cardiovascular and metabolic risk in outpatients with schizoaffective disorder treated with antipsychotics: Results from the CLAMORS study. *European Psychiatry*. 2012;27(4):267-274.
24. Pampel FC, Krueger PM, Denney JT. Socioeconomic disparities in health behaviors. *Annual review of sociology*. 2010;36:349-370.
25. Swinburn B, Egger G, Raza F. Dissecting obesogenic environments: The development and application of a framework for identifying and prioritizing environmental interventions for obesity. *Prev Med*. 1999;29(6):563-570.
26. Faulkner G, Cohn TA. Pharmacologic and nonpharmacologic strategies for weight gain and metabolic disturbance in patients treated with antipsychotic medications. *Canadian Journal of Psychiatry*. 2006;51(8):502-511.
27. Happell B, Scott D, Platania-Phung C, Nankivell J. Nurses' views on physical activity for people with serious mental illness. *Mental Health and Physical Activity*. 2012;5(1):4-12.
28. Vancampfort D, De Hert M, Skjerven LH, et al. International organization of physical therapy in mental health consensus on physical activity within multidisciplinary rehabilitation programmes for minimising cardio-metabolic risk in patients with schizophrenia. *Disabil Rehabil*. 2012;34(1):1-12.
29. Galletly CA, Foley DL, Waterreus A, et al. Cardiometabolic risk factors in people with psychotic disorders: The second Australian national survey of psychosis. *Australian and New Zealand Journal of Psychiatry*. 2012;46(8):753-761.

30. Leutwyler H, Hubbard EM, Jeste DV, Vinogradov S. "We're not just sitting on the periphery": A staff perspective of physical activity in older adults with schizophrenia. *The Gerontologist*. 2013;53(3):474-483.
31. Killackey EJ, Jackson HJ, Gleeson J, Hickie IB, McGorry PD. Exciting career opportunity beckons! early intervention and vocational rehabilitation in first-episode psychosis: Employing cautious optimism. *Australian and New Zealand Journal of Psychiatry*. 2006;40(11-12):951-962.
32. Ramsay CE, Stewart T, Compton MT. Unemployment among patients with newly diagnosed first-episode psychosis: Prevalence and clinical correlates in a US sample. *Soc Psychiatry Psychiatr Epidemiol*. 2011;47(5):797-803.
33. Gómez Pérez L, Santacana AM, Bergé Baguero D, Pérez-Solá V. Reasons and subjective effects of cannabis use among people with psychotic disorders: A systematic review. *Actas Españolas de Psiquiatría*. 2014;42(2):83-90.
34. Pristach CA, Smith CM. Self-reported effects of alcohol use on symptoms of schizophrenia. *PS*. 1996;47(4):421-423.
35. Torrey EF, Miller J, Rawlings R, Yolken RH. Seasonality of births in schizophrenia and bipolar disorder: A review of the literature. *Schizophr Res*. 1997;28(1):1-38.
36. Zittermann A, Schleithoff SS, Koerfer R. Putting cardiovascular disease and vitamin D insufficiency into perspective. *Br J Nutr*. 2005;94(04):483-492.
37. Holick MF, Binkley NC, Bischoff-Ferrari H, et al. Evaluation, treatment, and prevention of vitamin D deficiency: An endocrine society clinical practice guideline. *The Journal of Clinical Endocrinology & Metabolism*. 2011;96(7):1911-1930.
38. Eyles DW, Burne THJ, McGrath JJ. Vitamin D, effects on brain development, adult brain function and the links between low levels of vitamin D and neuropsychiatric disease. *Front Neuroendocrinol*. 2013;34(1):47-64.
39. McGrath J, Selten J, Chant D. Long-term trends in sunshine duration and its association with schizophrenia birth rates and age at first registration — data from australia and the netherlands. *Schizophr Res*. 2002;54(3):199-212.
40. Schneider B, Weber B, Frensch A, Stein J, Fritze J. Vitamin D in schizophrenia, major depression and alcoholism. *Journal of Neural Transmission*. 2000;107(7):839-842.
41. Yüksel RN, Altunsoy N, Tikir B, et al. Correlation between total vitamin D levels and psychotic psychopathology in patients with schizophrenia: Therapeutic implications for add-on vitamin D augmentation. *Therapeutic Advances in Psychopharmacology*. 2014;4(6):268-275.
42. Geleijnse JM. Vitamin D and the prevention of hypertension and cardiovascular diseases: A review of the current evidence. *American Journal of Hypertension*. 2011;24(3):253-262.
43. Ford ES, Zhao G, Li C, Pearson WS. Serum concentrations of vitamin D and parathyroid hormone and prevalent metabolic syndrome among adults in the united states. *Journal of Diabetes*. 2009;1(4):296-303.

44. Hyppönen E, Boucher BJ, Berry DJ, Power C. 25-hydroxyvitamin D, IGF-1, and metabolic syndrome at 45 years of age: A cross-sectional study in the 1958 british birth cohort. *Diabetes*. 2008;57(2):298-305.
45. Jorde R, Grimnes G. Vitamin D and metabolic health with special reference to the effect of vitamin D on serum lipids. *Prog Lipid Res*. 2011;50(4):303-312.
46. Saneei P, Salehi-Abargouei A, Esmailzadeh A. Serum 25-hydroxy vitamin D levels in relation to body mass index: A systematic review and meta-analysis. *Obesity Reviews*. 2013;14(5):393-404.
47. Scragg R, Sowers M, Bell C. Serum 25-hydroxyvitamin D, ethnicity, and blood pressure in the third national health and nutrition examination survey. *American Journal of Hypertension*. 2007;20(7):713-719.
48. Harrison J, Gill A. The experience and consequences of people with mental health problems, the impact of stigma upon people with schizophrenia: A way forward. *J Psychiatr Ment Health Nurs*. 2010;17(3):242-250.
49. Schulze B, Angermeyer MC. Subjective experiences of stigma. A focus group study of schizophrenic patients, their relatives and mental health professionals. *Soc Sci Med*. 2003;56(2):299-312.
50. Corrigan PW, River LP, Lundin RK, et al. Three strategies for changing attributions about severe mental illness. *Schizophrenia Bulletin*. 2001;27(2):187-195.
51. Hooley JM. Social factors in schizophrenia. *Current Directions in Psychological Science*. 2010;19(4):238-242.
52. van Zelst C. Stigmatization as an environmental risk in schizophrenia: A user perspective. *Schizophrenia Bulletin*. 2009;35(2):293-296.
53. Corrigan PW, Watson AC. The paradox of self-stigma and mental illness. *Clinical Psychology: Science and Practice*. 2002;9(1):35-53.
54. Omori Y, Mori C, White AH. Self-stigma in schizophrenia: A concept analysis. *Nurs Forum*. 2014;49(4):259-266.
55. Soundy A, Freeman P, Stubbs B, Probst M, Coffee P, Vancampfort D. The transcending benefits of physical activity for individuals with schizophrenia: A systematic review and meta-ethnography. *Psychiatry Res*. 2014;220(1-2):11-19.
56. Bobes J, Arango C, Garcia-Garcia M, Rojas J. Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders: An analysis of the impact of smoking tobacco in the CLAMORS schizophrenia cohort. *Schizophr Res*. 2010;119(1-3):101-109.
57. Stokes C, Peet M. Short communication. *Nutr Neurosci*. 2004;7(4):247-249.
58. WHO, FAO, eds. *Fruit and vegetables for health : Report of a joint FAO/WHO workshop*. Kobe: World Health Organization; 2004.

59. Hahn LA, Galletly CA, Foley DL, et al. Inadequate fruit and vegetable intake in people with psychosis. *Australian and New Zealand Journal of Psychiatry*. 2014;48(11):1025-1035.
60. Simonelli-Muñoz AJ, Fortea MI, Salorio P, Gallego-Gomez JI, Sánchez-Bautista S, Balanza S. Dietary habits of patients with schizophrenia: A self-reported questionnaire survey. *International Journal of Mental Health Nursing*. 2012;21(3):220-228.
61. Leenders M, Sluijs I, Ros MM, et al. Fruit and vegetable consumption and mortality: European prospective investigation into cancer and nutrition. *American Journal of Epidemiology*. 2013;178(4):590-602.
62. Roick C, Fritz-Wieacker A, Matschinger H, et al. Health habits of patients with schizophrenia. *Social Psychiatry and Psychiatric Epidemiology*. 2007;42(4):268-276.
63. Obarzanek E, Sacks FM, Vollmer WM, et al. Effects on blood lipids of a blood pressure-lowering diet: The dietary approaches to stop hypertension (DASH) trial. *The American Journal of Clinical Nutrition*. 2001;74(1):80-89.
64. Scott D, Happell B. The high prevalence of poor physical health and lifestyle behaviours in individuals with severe mental illness. *Issues in Mental Health Nursing*. 2011;32:589-597.
65. van Dam RM, Willett WC, Rimm EB, Stampfer MJ, Hu FB. Dietary fat and meat intake in relation to risk of type 2 diabetes in men. *Diabetes Care*. 2002;25(3):417-424.
66. Holick MF. Vitamin D deficiency. *N Engl J Med*. 2007;357(3):266-281.
67. Milligan RAK, Burke V, Beilin LJ, et al. Health-related behaviours and psycho-social characteristics of 18 year-old australians. *Soc Sci Med*. 1997;45(10):1549-1562.
68. Lindamer LA, McKibbin C, Norman GJ, et al. Assessment of physical activity in middle-aged and older adults with schizophrenia. *Schizophr Res*. 2008;104(1-3):294-301.
69. He D, Xi B, Xue J, Huai P, Zhang M, Li J. Association between leisure time physical activity and metabolic syndrome: A meta-analysis of prospective cohort studies. *Endocrine*. 2014;46(2):231-240.
70. Petersen CB, Nielsen AJ, Bauman A, Tolstrup JS. Joint association of physical activity in leisure and total sitting time with metabolic syndrome amongst 15,235 danish adults: A cross-sectional study. *Prev Med*. 2014;69:5-7.
71. Hartz SM, Pato CN, Medeiros H, et al. Comorbidity of severe psychotic disorder with measures of substance use. *Journal of the American Medical Association*. 2014;71(3):248-254.
72. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. *Journal of the American Medical Association*. 1990;264(19):2511-2518.
73. Groppelli A, Giorgi DM, Omboni S, Parati G, Mancia G. Persistent blood pressure increase induced by heavy smoking. *Journal of Hypertension*. 1992;10(5):495-499.

74. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension. *European Heart Journal*. 2013;34:2159-2219.
75. Willi C, Bodenmann P, Ghali WA, Faris PD, Cornuz J. Active smoking and the risk of type 2 diabetes: A systematic review and meta-analysis. *Journal of the American Medical Association*. 2007;298(22):2654-2664.
76. Rydén L, Grant PJ, Anker SD, et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The task force on diabetes, pre-diabetes, and cardiovascular diseases of the european society of cardiology (ESC) and developed in collaboration with the european association for the study of diabetes (EASD). *European Heart Journal*. 2013;34(39):3035-3087.
77. Corrao G, Bagnardi V, Zambon A, La Vecchia C. A meta-analysis of alcohol consumption and the risk of 15 diseases. *Prev Med*. 2004;38(5):613-619.
78. Slagter SN, van Vliet-Ostaptchouk JV, Vonk JM, et al. Combined effects of smoking and alcohol on metabolic syndrome: The Lifelines cohort study. *PLoS ONE*. 2014;9(4).
79. Tolstrup JS, Heitmann BL, Tjønneland AM, Overvad OK, Sørensen TI, Grønbaek MN. The relation between drinking pattern and body mass index and waist and hip circumference. *International Journal of Obesity*. 2005;29(5):490-497.
80. Sun K, Ren M, Liu D, Wang C, Yang C, Yan L. Alcohol consumption and risk of metabolic syndrome: A meta-analysis of prospective studies. *Clinical Nutrition*. 2014;33(4):596-602.
81. Kavanagh DJ, Waghorn G, Jenner L, et al. Demographic and clinical correlates of co-morbid substance use disorders in psychosis: Multivariate analyses from an epidemiological sample. *Schizophr Res*. 2004;66(2-3):115-124.
82. Sinclair JMA, Latifi AH, Latifi AW. Co-morbid substance misuse in psychiatric patients: Prevalence and association with length of inpatient stay. *Journal of Psychopharmacology*. 2008;22(1):92-99.
83. Kuepper R, Van Winkel R, Henquet C. Cannabis use and the risk of psychotic disorders. an update. *Tijdschrift voor Psychiatrie*. 2013;55(11):867-872.
84. Henquet C, van Os J, Kuepper R, et al. Psychosis reactivity to cannabis use in daily life: An experience sampling study. *The British Journal of Psychiatry*. 2010;196(6):447-453.
85. Semple DM, McIntosh AM, Lawrie SM. Cannabis as a risk factor for psychosis: Systematic review. *Journal of Psychopharmacology*. 2005;19(2):187-194.
86. Cantwell R. Substance use and schizophrenia: Effects on symptoms, social functioning and service use. *The British Journal of Psychiatry*. 2003;182(4):324-329.
87. Hahn L, Rigby A, Galletly C. Determinants of high rates of smoking among people with psychosis living in a socially disadvantaged region in south australia. *Australian and New Zealand Journal of Psychiatry*. 2014;48(1):70-79.



88. Jessen A, Buemann B, Toubro S, Skovgaard IM, Astrup A. The appetite-suppressant effect of nicotine is enhanced by caffeine\*. *Diabetes, Obesity and Metabolism*. 2005;7(4):327-333.
89. O'Reilly CL, Bell JS, Kelly PJ, Chen TF. Exploring the relationship between mental health stigma, knowledge and provision of pharmacy services for consumers with schizophrenia. *Research in Social and Administrative Pharmacy*. 2015;11(3):e101-e109.
90. Nordt C, Rössler W, Lauber C. Attitudes of mental health professionals toward people with schizophrenia and major depression. *Schizophrenia Bulletin*. 2006;32(4):709-714.
91. Montejo AL. The need for routine physical health care in schizophrenia. *European Psychiatry*. 2010;25, Supplement 2(0):S3-S5.
92. Larsen JT, Fagerquist M, Holdrup M, Christensen B, Sigalin C, Nilsson PM. Metabolic syndrome and psychiatrists' choice of follow-up interventions in patients treated with atypical antipsychotics in denmark and sweden. *Nord J Psychiatry*. 2011;65(1):40-46.
93. Cohn TA, Sernyak MJ. Metabolic monitoring for patients treated with antipsychotic medications. *Canadian Journal of Psychiatry*. 2006;51(8):492-501.
94. Mangurian C, Giwa F, Shumway M, et al. Primary care providers' views on metabolic monitoring of outpatients taking antipsychotic medication. *PS*. 2013;64(6):597-599.
95. Van Kerckhove C, De Kock C. *Ethiek en zorg in de hulpverlening. Over taboes gesproken*. Gent: Academia Press; 2013.
96. Werner F, Coveñas R. Safety of antipsychotic drugs: Focus on therapeutic and adverse effects. *Expert Opinion on Drug Safety*. 2014;13(8):1031-1042.
97. Chadda RK, Ramshankar P, Deb KS, Sood M. Metabolic syndrome in schizophrenia: Differences between antipsychotic naïve and treated patients. *Journal of Pharmacology and Pharmacotherapeutics*. 2013;4(3):176-186.
98. Bushe CJ, Slooff CJ, Haddad PM, Karagianis JL. Weight change by baseline BMI from three-year observational data: Findings from the worldwide schizophrenia outpatient health outcomes database. *Journal of Psychopharmacology*. 2013;0(0):1-8.
99. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis. *The Lancet*. 2013;382(9896):951-962.
100. Rummel-Kluge C, Komossa K, Schwarz S, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis. *Schizophr Res*. 2010;123(2-3):225-233.
101. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects - A comprehensive literature review. *CNS Drugs*. 2005;19(1):1-93.
102. American Diabetes Association. Tests of glycemia in diabetes. *Diabetes Care*. 2004;27(suppl 1):s91-s93.

103. Reynolds GP, Kirk SL. Metabolic side effects of antipsychotic drug treatment – pharmacological mechanisms. *Pharmacol Ther.* 2010;125(1):169-179.
104. Blouin M, Tremblay A, Jalbert M, et al. Adiposity and eating behaviors in patients under second generation antipsychotics. *Obesity.* 2008;16(8):1780-1787.
105. Johnson DE, Yamazaki H, Ward KM, et al. Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perfused rat islets: Role of muscarinic antagonism in antipsychotic-induced diabetes and hyperglycemia. *Diabetes.* 2005;54(5):1552-1558.
106. Weston-Green K, Huang X, Lian J, Deng C. Effects of olanzapine on muscarinic M3 receptor binding density in the brain relates to weight gain, plasma insulin and metabolic hormone levels. *European Neuropsychopharmacology.* 2012;22(5):364-373.
107. Kamphuis J, Taxis K, Schuiling-Veninga C, Bruggeman R, Lancel M. Off-label prescriptions of low-dose quetiapine and mirtazapine for insomnia in the netherlands. *J Clin Psychopharmacol.* 2015;35(4).
108. Hermes ED, Sernyak M, Rosenheck R. Use of second-generation antipsychotic agents for sleep and sedation: A provider survey. *Sleep.* 2013;36(4):597-600.
109. Velthorst E, Koeter M, van der Gaag M, et al. Adapted cognitive-behavioural therapy required for targeting negative symptoms in schizophrenia: Meta-analysis and meta-regression. *Psychol Med.* 2015;45(03):453-465.
110. Bird V, Premkumar P, Kendall T, Whittington C, Mitchell J, Kuipers E. Early intervention services, cognitive-behavioural therapy and family intervention in early psychosis: Systematic review. *The British Journal of Psychiatry.* 2010;197(5):350-356.
111. Álvarez-Jiménez M, Parker AG, Hetrick SE, McGorry PD, Gleeson JF. Preventing the second episode: A systematic review and meta-analysis of psychosocial and pharmacological trials in first-episode psychosis. *Schizophrenia Bulletin.* 2011;37(3):619-630.
112. Müller H, Laier S, Bechdolf A. Evidence-based psychotherapy for the prevention and treatment of first-episode psychosis. *European Archives of Psychiatry and Clinical Neuroscience.* 2014;264(Supplement 1):17-25.
113. Shi C, Yu X, Cheung EFC, Shum DHK, Chan RCK. Revisiting the therapeutic effect of rTMS on negative symptoms in schizophrenia: A meta-analysis. *Psychiatry Res.* 2014;215(3):505-513.
114. Maayan L, Correll CU. Management of antipsychotic-related weight gain. *Expert Review of Neurotherapeutics.* 2010;10(7):1175-1200.
115. Fernández-San-Martín MI, Martín-López LM, Masa-Font R, et al. The effectiveness of lifestyle interventions to reduce cardiovascular risk in patients with severe mental disorders: Meta-analysis of intervention studies. *Community Ment Health J.* 2013.
116. Bonfioli E, Berti L, Goss C, Muraro F, Burti L. Health promotion lifestyle interventions for weight management in psychosis: A systematic review and meta-analysis of randomised controlled trials. *BMC Psychiatry.* 2012;12(78).

117. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: An american heart Association/National heart, lung, and blood institute scientific statement. *Circulation*. 2005;112(17):2735-2752.
118. Nasrallah HA, Meyer JM, Goff DC, et al. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: Data from the CATIE schizophrenia trial sample at baseline. *Schizophr Res*. 2006;86(1-3):15-22.
119. Correll CU, Druss BG, Lombardo I, et al. Findings of a U.S. national cardiometabolic screening program among 10,084 psychiatric outpatients. *PS*. 2010;61(9):892-898.
120. The Lancet Psychiatry. Physical and mental health: Activate and integrate. *The Lancet Psychiatry*. 2014;1(3):163.
121. Correll CU. Balancing efficacy and safety in treatment with antipsychotics. *CNS Spectrums*. 2007;12(S17):12-20.
122. Correll CU, Robinson DG, Schooler NR, et al. Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: Baseline results from the RAISE-ETP study. *JAMA Psychiatry*. 2014;71(12):1350-1363.
123. Falissard B, Mauri M, Shaw K, et al. The METEOR study: Frequency of metabolic disorders in patients with schizophrenia. focus on first and second generation and level of risk in antipsychotic drugs. *International Clinical Psychopharmacology*. 2011;26(6):291-302.
124. Meyer JM, Stahl SM. The metabolic syndrome and schizophrenia. *Acta Psychiatr Scand*. 2009;119(1):4-14.
125. Mitchell AJ, Vancampfort D, Sweers K, van Winkel R, Yu W, De Hert M. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders—A systematic review and meta-analysis. *Schizophr Bull*. 2013;39(2):306-318.
126. Schorr SG, Slooff CJ, Bruggeman R, Taxis K. Prevalence of metabolic syndrome in patients with psychotic disorders in the netherlands. *J Clin Psychopharmacol*. 2009;29(4):399-402.
127. Laursen TM, Nordentoft M, Mortensen PB. Excess early mortality in schizophrenia. *Annu Rev Clin Psychol*. 2014;10(1):425-448.
128. Malan-Müller S, Kilian S, van den Heuvel LL, et al. A systematic review of genetic variants associated with metabolic syndrome in patients with schizophrenia. *Schizophr Res*. 2016;170(1):1-17.
129. Suvisaari JM, Saarni SI, Perälä J, et al. Metabolic syndrome among persons with schizophrenia and other psychotic disorders in a general population survey. *J Clin Psychiatry*. 2007;68(7):1045-1055.
130. Bruins J, Jörg F, Bruggeman R, Slooff C, Corpeleijn E, Pijnenborg M. The effects of lifestyle interventions on (long-term) weight management, cardiometabolic risk and depressive symptoms in people with psychotic disorders: A meta-analysis. *PLoS ONE*. 2014;9(12):December 5-e112276.

131. Risselada AJ, Vehof J, Bruggeman R, et al. Association between HTR2C gene polymorphisms and the metabolic syndrome in patients using antipsychotics: A replication study. *The Pharmacogenomics Journal*. 2012;12(1):62-67.
132. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. *Schizophrenia Bulletin*. 1987;13(2):261-276.
133. Andreasen NC, Carpenter WT, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: Proposed criteria and rationale for consensus. *The American Journal of Psychiatry*. 2005;162(3):441-449.
134. Forouhi NG, Balkau B, Borch-Johnsen K, et al. The threshold for diagnosing impaired fasting glucose: A position statement by the european diabetes epidemiology group. *Diabetologia*. 2006;49(5):822-827.
135. WHO. *Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia. report of a WHO/IDF consultation*. Geneva: WHO Document Production Services; 2006.
136. Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community. *The Journal of Clinical Hypertension*. 2014;16(1):14-26.
137. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the american college of Cardiology/American heart association task force on practice guidelines. *Circulation*. 2014;129(25 suppl 2):S1-S45.
138. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: A patient-centered approach: Position statement of the american diabetes association (ADA) and the european association for the study of diabetes (EASD). *Diabetes Care*. 2012;35(6):1364-1379.
139. Goff DC, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: A report of the american college of Cardiology/American heart association task force on practice guidelines. *Circulation*. 2013.
140. Mancia G, Agabiti Rosei E, Cifkova R, et al. 2003 european society of hypertension-european society of cardiology guidelines for the management of arterial hypertension. *Journal of Hypertension*. 2003;21(6):1011-1053.
141. Mancia G, De Backer G, Dominiczak A, et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial hypertension: ESH-ESC Task force on the Management of Arterial hypertension. *Journal of Hypertension*. 2007;25(10):1751-1762.
142. Conroy RM, Pyörälä K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in europe: The SCORE project. *European Heart Journal*. 2003;24(11):987-1003.
143. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. *European Heart Journal*. 2003;24:1601-1610.

144. Reiner Ž, Catapano AL, De Backer G, et al. ESC/EAS guidelines for the management of dyslipidaemias: The task force for the management of dyslipidaemias of the european society of cardiology (ESC) and the european atherosclerosis society (EAS) *European Heart Journal*. 2011;32(14):1769-1818.
145. IDF Clinical Guidelines Task Force. *Global guideline for type 2 diabetes*. Brussels: International Diabetes Federation; 2005. <https://www.idf.org>
146. IDF Clinical Guidelines Task Force. *Global guideline for type 2 diabetes*. Brussels: International Diabetes Federation; 2012.
147. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. *Diabetes Care*. 2003;26(11):3160-3167.
148. Isaac M, Isaac M, Holloway F. Is cannabis an anti-antipsychotic? the experience in psychiatric intensive care. *Hum Psychopharmacol Clin Exp*. 2005;20(3):207-210.
149. IBM Corp. IBM SPSS statistics for windows, version 22.0. . 2013.
150. National Institute for Public Health and the Environment. Prevalence of the metabolic syndrome. divided by age and gender. [www.rivm.nl](http://www.rivm.nl). Updated 2012.
151. Termorshuizen F, Wierdsma AI, Smeets HM, et al. Cause-specific mortality among patients with psychosis: Disentangling the effects of age and illness duration. *Psychosomatics*. 2013;54(6):536-545.
152. Joffres M, Falaschetti E, Gillespie C, et al. Hypertension prevalence, awareness, treatment and control in national surveys from england, the USA and canada, and correlation with stroke and ischaemic heart disease mortality: A cross-sectional study. *BMJ Open*. 2013;3(8).
153. Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: Global estimates of the prevalence of diabetes for 2011 and 2030. *Diabetes Res Clin Pract*. 2011;94(3):311-321.
154. Centers for Disease Control and Prevention. *National diabetes statistics report: Estimates of diabetes and its burden in the united states, 2014*. Atlanta: US Department of Health and Human Services; 2014.
155. Goff DC, Bertoni AG, Kramer H, et al. Dyslipidemia prevalence, treatment, and control in the multi-ethnic study of atherosclerosis (MESA): Gender, ethnicity, and coronary artery calcium. *Circulation*. 2006;113(5):647-656.
156. Rathmann W, Pscherer S, Konrad M, Kostev K. Diabetes treatment in people with type 2 diabetes and schizophrenia: Retrospective primary care database analyses. *Primary Care Diabetes*.
157. Osborn DPJ, Hardoon S, Omar RZ, et al. Cardiovascular risk prediction models for people with severe mental illness: Results from the prediction and management of cardiovascular risk in people with severe mental illnesses (PRIMROSE) research program. *JAMA Psychiatry*. 2015;72(2):143-151.

158. De Hert M, van Winkel R, Silic A, Van Eyck D, Peuskens J. Physical health management in psychiatric settings. *European Psychiatry*. 2010;25, Supplement 2(0):S22-S28.
159. Druss BG, Rohrbaugh RM, Levinson CM, Rosenheck RA. Integrated medical care for patients with serious psychiatric illness: A randomized trial. *Archives of General Psychiatry*. 2001;58(9):861-868.
160. Millar H. Management of physical health in schizophrenia: A stepping stone to treatment success. *European Neuropsychopharmacology*. 2008;18, Supplement 2(0):S121-S128.
161. Fernandes de Abreu DA, Eyles D, Féron F. Vitamin D, a neuro-immunomodulator: Implications for neurodegenerative and autoimmune diseases. *Psychoneuroendocrinology*. 2009;34, Supplement 1:S265-S277.
162. Kalueff AV, Tuohimaa P. Neurosteroid hormone vitamin D and its utility in clinical nutrition. *Current Opinion in Clinical Nutrition & Metabolic Care*. 2007;10(1).
163. Strange RC, Shipman KE, Ramachandran S. Metabolic syndrome: A review of the role of vitamin D in mediating susceptibility and outcome. *World Journal of Diabetes*. 2015;6(7):896-911.
164. Grant WB, Wimalawansa SJ, Holick MF, et al. Emphasizing the health benefits of vitamin D for those with neurodevelopmental disorders and intellectual disabilities. *Nutrients*. 2015;7(3):1538-1564.
165. Hyppönen E, Power C. Vitamin D status and glucose homeostasis in the 1958 british birth cohort: The role of obesity. *Diabetes Care*. 2006;29(10):2244-2246.
166. Ginde AA, Scragg R, Schwartz RS, Camargo CA. Prospective study of serum 25-hydroxyvitamin D level, cardiovascular disease mortality, and all-cause mortality in older U.S. adults. *J Am Geriatr Soc*. 2009;57(9):1595-1603.
167. Kendrick J, Targher G, Smits G, Chonchol M. 25-hydroxyvitamin D deficiency is independently associated with cardiovascular disease in the third national health and nutrition examination survey. *Atherosclerosis*. 2009;205(1):255-260.
168. Kilkinen A, Knekt P, Aro A, et al. Vitamin D status and the risk of cardiovascular disease death. *American Journal of Epidemiology*. 2009;170(8):1032-1039.
169. Pittas AG, Lau J, Hu FB, Dawson-Hughes B. The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. *The Journal of Clinical Endocrinology & Metabolism*. 2007;92(6):2017-2029.
170. Scragg R, Sowers M, Bell C. Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the third national health and nutrition examination survey. *Diabetes Care*. 2004;27(12):2813-2818.
171. Wang L, Song Y, Manson JE, et al. Circulating 25-hydroxy-vitamin D and risk of cardiovascular disease: A meta-analysis of prospective studies. *Circulation: Cardiovascular Quality and Outcomes*. 2012;5(6):819-829.

172. Garland CF, Kim JJ, Mohr SB, et al. Meta-analysis of all-cause mortality according to serum 25-hydroxyvitamin D. *Am J Public Health*. 2014;104(8):e43-e50.
173. Lee JH, O'Keefe JH, Bell D, Hensrud DD, Holick MF. Vitamin D deficiency: An important, common, and easily treatable cardiovascular risk factor? *J Am Coll Cardiol*. 2008;52(24):1949-1956.
174. Chiang M, Natarajan R, Fan X. Vitamin D in schizophrenia: A clinical review. *Evidence Based Mental Health*. 2016;19(1):6-9.
175. Hedelin M, Lof M, Olsson M, et al. Dietary intake of fish, omega-3, omega-6 polyunsaturated fatty acids and vitamin D and the prevalence of psychotic-like symptoms in a cohort of 33 000 women from the general population. *BMC Psychiatry*. 2010;10(1):38.
176. Graham KA, Keefe RS, Lieberman JA, Calikoglu AS, Lansing KM, Perkins DO. Relationship of low vitamin D status with positive, negative and cognitive symptom domains in people with first-episode schizophrenia. *Early Intervention in Psychiatry*. 2015;9(5):397-405.
177. Cieslak K, Feingold J, Antonius D, et al. Low vitamin D levels predict clinical features of schizophrenia. *Schizophr Res*. 2014;159(2-3):543-545.
178. Ottesen Berg A, Melle I, Torjesen PA, Lien L, Hauff E, Andreassen OA. A cross-sectional study of vitamin D deficiency among immigrants and norwegians with psychosis compared to the general population. *Journal of Clinical Psychiatry*. 2010;71(12):1598-1604.
179. Itzhaky D, Amital D, Gorden K, Bogomolni A, Arnson Y, Amital H. Low serum vitamin D concentrations in patients with schizophrenia. *Israel Medical Association Journal*. 2012;14(2):88-92.
180. Cui X, Pertile R, Liu P, Eyles DW. Vitamin D regulates tyrosine hydroxylase expression: N-cadherin a possible mediator. *Neuroscience*. 2015;304:90-100.
181. Cui X, Groves NJ, Burne TH, Eyles DW, McGrath JJ. Low vitamin D concentration exacerbates adult brain dysfunction. *The American Journal of Clinical Nutrition*. 2013;97(5):907-908.
182. Groves NJ, McGrath JJ, Burne THJ. Vitamin D as a neurosteroid affecting the developing and adult brain. *Annu Rev Nutr*. 2014;34(1):117-141.
183. Buchanan RW, Freedman R, Javitt DC, Abi-Dargham A, Lieberman JA. Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. *Schizophr Bull*. 2007;33(5):1120-1130.
184. Bergqvist A, Karlsson M, Foldemo A, Wärdig R, Hultsjö S. Preventing the development of metabolic syndrome in people with psychotic Disorders—Difficult, but possible: Experiences of staff working in psychosis outpatient care in sweden. *Issues Ment Health Nurs*. 2013;34(5):350-358.
185. Brown S, Birtwistle J, Roe L, Thompson C. The unhealthy lifestyle of people with schizophrenia. *Psychological Medicine*. 1999;29(3):697-701.



186. Rosecrans R, Dohnal JC. Seasonal vitamin D changes and the impact on health risk assessment. *Clin Biochem.* 2014;47(7–8):670-672.
187. Byrne EM, Raheja U, Stephens SH, et al. Seasonality shows evidence for polygenic architecture and genetic correlation with schizophrenia and bipolar disorder – a meta-analysis of genetic studies. *J Clin Psychiatry.* 2015;76(2):128-134.
188. Bruins J, Pijnenborg MG, Bartels-Velthuis AA, et al. Cannabis use in people with severe mental illness: The association with physical and mental health – a cohort study. A pharmacotherapy monitoring and outcome survey study. *Journal of Psychopharmacology.* 2016.
189. Jones G. Metabolism and biomarkers of vitamin D. *Scandinavian Journal of Clinical & Laboratory Investigation.* 2012;243:7-13.
190. Pekelharing JM, Blankenstein MA, van Haard PMM. Referentiewaarden klinische chemie. [www.farmacotherapeutischkompas.nl](http://www.farmacotherapeutischkompas.nl). Updated 2016.
191. Sobel ME. Asymptotic confidence intervals for indirect effects in structural equation models. *Sociological Methodology.* 1982;13:290-312.
192. Valipour G, Saneei P, Esmailzadeh A. Serum vitamin D levels in relation to schizophrenia: A systematic review and meta-analysis of observational studies. *The Journal of Clinical Endocrinology & Metabolism.* 2014;99(10):3863-3872.
193. Verkaik-Kloosterman J, van Valkengoed IGM, de Boer EJ, Nicolaou M, van der A DL. Nutritional status of asian and african surinamese and ethnic dutch in the netherlands – the SUNSET study. . 2011;350070003.
194. von Känel R, Fardad N, Steurer N, et al. Vitamin D deficiency and depressive symptomatology in psychiatric patients hospitalized with a current depressive episode: A factor analytic study. *PLoS ONE.* 2015;10(9):e0138550.
195. O’Connell SE, Griffiths PL, Cledes SA. Seasonal variation in physical activity, sedentary behaviour and sleep in a sample of UK adults. *Ann Hum Biol.* 2014;41(1):1-8.
196. Witham MD, Donnan PT, Vadiveloo T, et al. Association of day length and weather conditions with physical activity levels in older community dwelling people. *PLoS ONE.* 2013;9(1):e85331.
197. Dang R, Jiang P, Cai H, et al. Vitamin D deficiency exacerbates atypical antipsychotic-induced metabolic side effects in rats: Involvement of the INSIG/SREBP pathway. *European Neuropsychopharmacology.* 2015;25(8):1239-1247.
198. Challengomas D. Vitamin D supplementation and lipid profile: What does the best available evidence show? *Atherosclerosis.* 2014;235(1):130-139.
199. Jorde R, Figenschau Y. Supplementation with cholecalciferol does not improve glycaemic control in diabetic subjects with normal serum 25-hydroxyvitamin D levels. *Eur J Nutr.* 2009;48(6):349-354.



200. Pittas AG, Harris SS, Stark PC, Dawson-Hughes B. The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in nondiabetic adults. *Diabetes Care*. 2007;30(4):980-986.
201. Meems LMG, de Borst MH, Postma DS, et al. Low levels of vitamin D are associated with multimorbidity: Results from the LifeLines cohort study. *Ann Med*. 2015;47(6):474-481.
202. Wacker M, Holick MF. Sunlight and vitamin D: A global perspective for health. *Dermato-endocrinology*. 2013;5(1):51-108.
203. Datta P, Bogh MK, Olsen P, et al. Increase in serum 25-hydroxyvitamin-D3 in humans after solar exposure under natural conditions compared to artificial UVB exposure of hands and face. - *Photochem Photobiol Sci*. (- 12):- 1817.
204. Atmaca M, Kuloglu M, Tezcan E, Ustundag B. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. *Journal of Clinical Psychiatry*. 2003;64(5):598-604.
205. Haupt DW, Newcomer JW. Hyperglycemia and antipsychotic medications. *Journal of Clinical Psychiatry*. 2001;62(Suppl 27):15-26.
206. Green B, Young R, Kavanagh D. Cannabis use and misuse prevalence amongst people with psychosis. *British Journal of Psychiatry*. 2005;187:306-313.
207. Le Strat Y, Le Foll B. Obesity and cannabis use: Results from 2 representative national surveys. *American Journal of Epidemiology*. 2011;174(8):929-933.
208. Penner EA, Buettner H, Mittleman MA. The impact of marijuana use on glucose, insulin, and insulin resistance among US adults. *Am J Med*. 2013;126(7):583-589.
209. Smit E, Crespo CJ. Dietary intake and nutritional status of US adult marijuana users: Results from the third national health and nutrition examination survey. *Public Health Nutr*. 2001;4(03):781-786.
210. Warren M, Frost-Pineda K, Gold M. Body mass index and marijuana use. *Journal of Addictive Diseases*. 2005;24(3):95-100.
211. Rodondi N, Pletcher MJ, Liu K, Hulley SB, Sidney S. Marijuana use, diet, body mass index, and cardiovascular risk factors (from the CARDIA study). *Am J Cardiol*. 2006;98(4):478-484.
212. Mulder CL, Van der Gaag M, Bruggeman R, et al. Routine outcome monitoring for patients with severe mental illness: A consensus document. *Tijdschrift voor Psychiatrie*. 2010;52(3):169-179.
213. Thalheimer W, Cooks S. How to calculate effect sizes from published research articles: A simplified methodology. . 2002.
214. Rubin DB. *Multiple imputation for non-response in surveys*. New York, USA: John Wiley and Sons; 2004.

215. EMCDDA - European Monitoring Centre for Drugs and Drug Addiction. *2012 annual report on the state of the drugs problem in europa*. Luxembourg: Publications Office of the European Union; 2012.
216. Meijer JH, Dekker N, Koeter MW, Quee PJ, van Beveren NJM, Meijer CJ. Cannabis and cognitive performance in psychosis: A cross-sectional study in patients with non-affective psychotic illness and their unaffected siblings. *Psychol Med*. 2012;42(04):705-716.
217. Manrique-Garcia E, Zammit S, Dalman C, Hemmingsson T, Andreasson S, Allebeck P. Cannabis, schizophrenia and other non-affective psychoses: 35 years of follow-up of a population-based cohort. *Psychol Med*. 2012;42(06):1321-1328.
218. Matias I, Di Marzo V. Endocannabinoids and the control of energy balance. *Trends in Endocrinology & Metabolism*. 2007;18(1):27-37.
219. Juan C, Chen K, Wang P, Hwang J, Seow K. Endocannabinoid system activation may be associated with insulin resistance in women with polycystic ovary syndrome. *Fertil Steril*. 2015;104(1):200-206.
220. Hillig KW, Mahlberg PG. A chemotaxonomic analysis of cannabinoid variation in cannabis (cannabaceae). *American Journal of Botany*. 2004;91(6):966-975.
221. Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. *Nature Neuroscience*. 2005;8:585-589.
222. Christopoulou FD, Kiortsis DN. An overview of the metabolic effects of rimonabant in randomized controlled trials: Potential for other cannabinoid 1 receptor blockers in obesity. *J Clin Pharm Ther*. 2011;36(1):10-18.
223. Waterlow M, Chrisp P. Rimonabant: The evidence for its use in the treatment of obesity and the metabolic syndrome. *Core Evidence*. 2008;2(3):173-187.
224. Curioni C, Charles A. Rimonabant for overweight or obesity. *Cochrane Database of Systematic Reviews*. 2006;18(4).
225. Oleson EB, Cheer JF. A brain on cannabinoids: The role of dopamine release in reward seeking. *Cold Spring Harbor Perspectives in Medicine*. 2012;2(8).
226. Small DM, Jones-Gotman M, Dagher A. Feeding-induced dopamine release in dorsal striatum correlates with meal pleasantness ratings in healthy human volunteers. *Neuroimage*. 2003;19(4):1709-1715.
227. Foti DJ, Kotov R, Guey LT, Bromet EJ. Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization. *American Journal of Psychiatry*. 2010;167(8):987-993.
228. Negrete JC, Knapp WP, Douglas DE, Smith WB. Cannabis affects the severity of schizophrenic symptoms: Results of a clinical survey. *Psychol Med*. 1986;16(03):515-520.
229. Peralta V, Cuesta MJ. Influence of cannabis abuse on schizophrenic psychopathology. *Acta Psychiatr Scand*. 1992;85(2):127-130.

230. Henchoz Y, Dupuis M, Deline S, et al. Associations of physical activity and sport and exercise with at-risk substance use in young men: A longitudinal study. *Prev Med.* 2014;64(0):27-31.
231. Lee JO, Hill KG, Hartigan LA, et al. Unemployment and substance use problems among young adults: Does childhood low socioeconomic status exacerbate the effect? *Soc Sci Med.* 2015;143:36-44.
232. DANIEL JZ, HICKMAN M, MACLEOD J, et al. Is socioeconomic status in early life associated with drug use? A systematic review of the evidence. *Drug Alcohol Rev.* 2009;28(2):142-153.
233. Drewnowski A, Moudon AV, Jiao J, Aggarwal A, Charreire H, Chaix B. Food environment and socioeconomic status influence obesity rates in seattle and in paris. *International Journal of Obesity.* 2013;38(2):306-314.
234. Kim JY, Kim SH, Cho YJ. Socioeconomic status in association with metabolic syndrome and coronary heart disease risk. *Korean Journal of Family Medicine.* 2013;34(2):131-138.
235. Schoepf D, Potluri R, Uppal H, Natalwala A, Narendran P, Heun R. Type-2 diabetes mellitus in schizophrenia: Increased prevalence and major risk factor of excess mortality in a naturalistic 7-year follow-up. *European Psychiatry.* 2012;27(1):33-42.
236. Weiland BJ, Thayer RE, Depue BE, Sabbineni A, Bryan AD, Hutchison KE. Daily marijuana use is not associated with brain morphometric measures in adolescents or adults. *The Journal of Neuroscience.* 2015;35(4):1505-1512.
237. Padmanabhan JL, Tandon N, Haller CS, et al. Correlations between brain structure and symptom dimensions of psychosis in schizophrenia, schizoaffective, and psychotic bipolar I disorders. *Schizophrenia Bulletin.* 2015;41(1):154-162.
238. Britvic D, Maric NP, Doknic M, et al. Metabolic issues in psychotic disorders with the focus on first-episode patients: A review. *Psychiatria Danubia.* 2013;25(4):410-415.
239. Laursen TM, Wahlbeck K, H  llgren J, et al. Life expectancy and death by diseases of the circulatory system in patients with bipolar disorder or schizophrenia in the nordic countries. *PLoS ONE.* 2013;8(6):e67133.
240. Casey DA, Rodriguez M, Northcott C, Vickar G, Shihabuddin L. Schizophrenia: Medical illness, mortality, and aging. *The International Journal of Psychiatry in Medicine.* 2011;41(3):245-251.
241. O'Connor N, Hunt GE, O'Hara-Aarons M, et al. The sydney mental health client mortality audit: What does it tell us and what are we to do? *Australasian Psychiatry.* 2014;22(2):154-159.
242. Steiner J, Bernstein H, Schiltz K, et al. Immune system and glucose metabolism interaction in schizophrenia: A chicken-egg dilemma. *Prog Neuro-Psychopharmacol Biol Psychiatry.* 2014;48:287-294.

243. Van Winkel R, Genetic Risk and Outcome of Psychosis (GROUP) Investigators. Family-based analysis of genetic variation underlying psychosis-inducing effects of cannabis: Sibling analysis and proband follow-up. *Archives of General Psychiatry*. 2011;68(2):148-157.
244. Harmon BT, Devaney SA, Gordish-Dressman H, et al. Functional characterization of a haplotype in the AKT1 gene associated with glucose homeostasis and metabolic syndrome. *Human Genetics*. 2010;128(6):635-645.
245. Ozaita A, Puighermanal E, Maldonado R. Regulation of PI3K/Akt/GSK-3 pathway by cannabinoids in the brain. *J Neurochem*. 2007;102(4):1105-1114.
246. Sanchez MG, Ruiz-Llorente L, Sanchez AM, Diaz-Laviada I. Activation of phosphoinositide 3-kinase/PKB pathway by CB1 and CB2 cannabinoid receptors expressed in prostate PC-3 cells. involvement in raf-1 stimulation and NGF induction. *Cell Signal*. 2003;15(9):851-859.
247. Korver N, Quee PJ, Boos HBM, Simons CJP, de Haan L, GROUP investigators. Genetic risk and outcome of psychosis (GROUP), a multi site longitudinal cohort study focused on gene?environment interaction: Objectives, sample characteristics, recruitment and assessment methods. *International Journal of Methods in Psychiatric Research*. 2012;21(3):205-221.
248. Cordell HJ, Clayton DG. Genetic association studies. *The Lancet*. 2005;366(9491):1121-1131.
249. van Winkel R, van Beveren N,J.M., Simons C, Genetic Risk and Outcome,of Psychosis. AKT1 moderation of cannabis-induced cognitive alterations in psychotic disorder. *Neuropsychopharmacology*. 2011;36(12):2529-2537.
250. McKenzie JA, Witkowski S, Ludlow AT, Roth SM, Hagberg JM. AKT1 G205T genotype influences obesity-related metabolic phenotypes and their responses to aerobic exercise training in older caucasians. *Exp Physiol*. 2010;96(3):338-347.
251. American Psychiatric Association. *Diagnostics and statistical manual of mental disorders*. 5th ed. Arlington, VA: American Psychiatric Publishing; 2013.
252. Dickerson FB, Brown CH, Kreyenbuhl JA, et al. Obesity among individuals with serious mental illness. *Acta Psychiatr Scand*. 2006;113(4):306-313.
253. Colton CW, Manderscheid RW. Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states. *Preventing Chronic Disease*. 2006;3:A42.
254. NICE. Psychosis and schizophrenia in adults: Treatment and management [CG178]. [www.nice.org.uk](http://www.nice.org.uk) Updated 2014.
255. Mueser KT, Deavers F, Penn DL, Cassisi J. Psychosocial treatments for schizophrenia. *Annual Review of Clinical Psychology*. 2013;9(25):25.1-25.33.
256. Plourde G, Prud'homme D. Managing obesity in adults in primary care. *Can Med Assoc J*. 2012;184(9):1039-1044.

257. Verhaege N, De Maeseneer J, Maes L, Van Heeringen C, Annemans L. Effectiveness and cost-effectiveness of lifestyle interventions on physical activity and eating habits in persons with severe mental disorders: A systematic review. *International Journal of Behavioral Nutrition and Physical Activity*. 2011;8(28).
258. Gabriele J, Dubbert P, Reeves R. Efficacy of behavioural interventions in managing atypical antipsychotic weight gain. *Obesity reviews*. 2009;10:442-455.
259. Caemmerer J, Correll CU, Maayan L. Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: A meta-analytic comparison of randomized controlled trials. *Schizophr Res*. 2012;140(1-3):159-168.
260. Cimo A, Stergiopoulos E, Cheng C, Bonato S, Dewa C. Effective lifestyle interventions to improve type II diabetes self-management for those with schizophrenia or schizoaffective disorder: A systematic review. *BMC Psychiatry*. 2012;12(1):24.
261. Nover C, Jackson S. Primary care-based educational interventions to decrease risk factors for metabolic syndrome for adults with major psychotic and/or affective disorders: A systematic review. *Systematic Reviews*. 2013;2(1):116.
262. Álvarez-Jiménez M, Martínez-García O, Pérez-Iglesias R, Ramírez ML, Vázquez-Barquero JL, Crespo-Facorro B. Prevention of antipsychotic-induced weight gain with early behavioural intervention in first-episode psychosis: 2-year results of a randomized controlled trial. *Schizophr Res*. 2010;116(1):16-19.
263. Brown C, Goetz J, Hamera E. Weight loss intervention for people with serious mental illness: A randomized controlled trial of the RENEW program. *Psychiatric Services*. 2011;62(7):800-802.
264. Evans S, Newton R, Higgins S. Nutritional intervention to prevent weight gain in patients commenced on olanzapine: A randomized controlled trial. *Aust N Z J Psychiatry*. 2005;39(6):479-486.
265. Khazaal Y, Fresard E, Rabia S, et al. Cognitive behavioural therapy for weight gain associated with antipsychotic drugs. *Schizophr Res*. 2007;91(1-3):169-177.
266. Littrell KH, Hilligoss NM, Kirshner CD, Petty RG, Johnson CG. The effects of an educational intervention on antipsychotic-induced weight gain. *Journal of Nursing Scholarship*. 2003;35(3):237-241.
267. McKibbin CL, Golshan S, Griver K, Kitchen K, Wykes TL. A healthy lifestyle intervention for middle-aged and older schizophrenia patients with diabetes mellitus: A 6-month follow-up analysis. *Schizophr Res*. 2010;121(1-3):203-206.
268. Attux C, Martini L, Elks H, et al. A 6-month randomized controlled trial to test the efficacy of a lifestyle intervention for weight gain management in schizophrenia. *BMC Psychiatry*. 2013;13(1):60.
269. House A, Bostock J, Cooper J. Depressive syndromes in the year following onset of a first schizophrenic illness. *British Journal of Psychiatry*. 1987;151(1987):773-779.

270. Subotnik KL, Nuechterlein KH, Asarnow RF, Fogelson DL, Goldstein MJ, Talovic SA. Depressive symptoms in the early course of schizophrenia: Relationship to familial psychiatric illness. 1997. *American Journal of Psychiatry*;154(1997):1551-1556.
271. Wassink TH, Flaum M, Nopoulos P, Andreasen NC. Prevalence of depressive symptoms early in the course of schizophrenia. *American Journal of Psychiatry*. 1999;156:315-316.
272. Sands JR, Harrow M. Depression during the longitudinal course of schizophrenia. *Schizophrenia Bulletin*. 1999;25:157-171.
273. Tarrier N, Wykes T. Is there evidence that cognitive behaviour therapy is an effective treatment for schizophrenia? A cautious or cautionary tale? *Behav Res Ther*. 2004;42(12):1377-1401.
274. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *British Medical Journal*. 2003;327:557-560.
275. Cooper HM, Hedges LV. *The handbook of research synthesis*. New York: Russel Sage Foundation; 1994.
276. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. *International Journal of Surgery*. 2010;8(5):336-341.
277. Cochran WG. The combination of estimates from different experiments. *Biometrics*. 1954;10(1):101-129.
278. Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ*. 1997;315(7109):629-634.
279. Ball PM, Coons VB, Buchanan RW. A program for treating olanzapine-related weight gain. *Psychiatric Services*. 2001;52(7):967-969.
280. Melamed Y, Stein-Reisner O, Gelkopf M, et al. Multi-modal weight control intervention for people with persistent mental disorders. *Psychiatric Rehabilitation Journal*. 2008;31(3):194-200.
281. Porsdal V, Beal C, Kleivenes OK, et al. The scandinavian solutions for wellness study - a two-arm observational study on the effectiveness of lifestyle intervention on subjective well-being and weight among persons with psychiatric disorders. *BMC Psychiatry*. 2010;10:42.
282. Voruganti LNP, Watham J, Bard E, et al. Going beyond: An adventure- and recreation-based group intervention promotes well-being and weight loss in schizophrenia. *The Canadian Journal of Psychiatry*. 2006;51(9):575-580.
283. Vreeland B, Minsky S, Gara MA, et al. Solutions for wellness: Results of a manualized psychoeducational program for adults with psychiatric disorders. *American Journal of Psychiatric Rehabilitation*. 2010;13:55-72.

284. McCreddie RG, Kelly C, Connolly M, et al. Dietary improvement in people with schizophrenia: Randomised controlled trial. *British Journal of Psychiatry*. 2005;187:346-351.
285. Ching HY, Wu SL, Chen WC, Hsieh CL. Effects of auricular acupressure on body weight parameters in patients with chronic schizophrenia. *Evidence-Based Complementary and Alternative Medicine*. 2012.
286. Brown S, Chan K. A randomized controlled trial of a brief health promotion intervention in a population with serious mental illness. *Journal of Mental Health*. 2006;15(5):543-549.
287. Brown S, Smith E. Can a brief health promotion intervention delivered by mental health key workers improve clients' physical health: A randomized controlled trial. *Journal of Mental Health*. 2009;18(5):372-378.
288. Milano W, Grillo F, Del Mastro A, et al. Appropriate intervention strategies for weight gain induced by olanzapine: A randomized controlled study. *Advances in Therapy*. 2007;24(1):123-134.
289. Poulin M, Chaput J, Simard V, et al. Management of antipsychotic-induced weight gain: Prospective naturalistic study of the effectiveness of a supervised exercise programme. *Aust N Z J Psychiatry*. 2007;41(12):980-989.
290. Scocco P, Longo R, Caon F. Weight change in treatment with olanzapine and a psycho-educational approach. *Eating Behav*. 2006;7(2):115-124.
291. Skrinar GS, Huxley NA, Hutchinson DS, Menninger E, Glew P. The role of a fitness intervention on people with serious psychiatric disabilities. *Psychiatr Rehabil J*. 2005;29(2):122-127.
292. Brar JS, Ganguli R, Pandina G, Turkoz I, Berry S, Mahmoud R. Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder. *J Clin Psychiatry*. 2005;66(2):205-212.
293. Daumit GL, Dickerson FB, Wang N, et al. A behavioral weight-loss intervention in persons with serious mental illness. *N Engl J Med*. 2013;368(17):1594-1602.
294. Jean-Baptiste M, Tek C, Liskov E, et al. A pilot study of a weight management program with food provision in schizophrenia. *Schizophr Res*. 2007;96(1-3):198-205.
295. McKibbin CL, Patterson TL, Norman G, et al. A lifestyle intervention for older schizophrenia patients with diabetes mellitus: A randomized controlled trial. *Schizophr Res*. 2006;86(1-3):36-44.
296. Weber M, Wyne K. A cognitive/behavioral group intervention for weight loss in patients treated with atypical antipsychotics. *Schizophr Res*. 2006;83(1):95-101.
297. Álvarez-Jiménez M, González-Blanch C, Vázquez-Barquero JL, et al. Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naïve first-episode psychosis patients: A randomized controlled trial. *J Clin Psychiatry*. 2006;67(8):1253-1260.



298. Iglesias-García C, Toimil-Iglesias A, Alonso-Villa M. Pilot study of the efficacy of an educational programme to reduce weight, on overweight and obese patients with chronic stable schizophrenia. *J Psychiatr Ment Health Nurs*. 2010;17(9):849-851.
299. Mauri M, Simoncini M, Castrogiovanni S, et al. A psychoeducational program for weight loss in patients who have experienced weight gain during antipsychotic treatment with olanzapine. *Pharmacopsychiatry*. 2008;41(1):17-23.
300. Forsberg KA, Björkman T, Sandman PO, Sandlund M. Physical health—A cluster randomized controlled lifestyle intervention among persons with a psychiatric disability and their staff. *Nordic Journal of Psychiatry*. 2008;62(6):486-495.
301. Scheewe TW, Backx FJG, Takken T, et al. Exercise therapy improves mental and physical health in schizophrenia: A randomised controlled trial. *Acta Psychiatr Scand*. 2013;127(6):464-473.
302. Kwon JS, Choi J, Bahk W, et al. Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder: A 12-week randomized controlled clinical trial. *J Clin Psychiatry*. 2006;67(4):547-553.
303. Methapatara W, Srisurapanont M. Pedometer walking plus motivational interviewing program for thai schizophrenic patients with obesity or overweight: A 12-week, randomized, controlled trial. *Psychiatry Clin Neurosci*. 2011;65(4):374-380.
304. Wu M, Wang C, Bai Y, Huang C, Lee S. Outcomes of obese, clozapine-treated inpatients with schizophrenia placed on a six-month diet and physical activity program. *Psychiatric Services*. 2007;58(4):544-550.
305. Wu R, Zhao J, Jin H, et al. Lifestyle intervention and metformin for the treatment of antipsychotic-induced weight gain: A randomized controlled trial. *JAMA: Journal of the American Medical Association*. 2008;299(2):185-193.
306. Bo S, Ciccone G, Baldi C, et al. Effectiveness of a lifestyle intervention on metabolic syndrome. A randomized controlled trial. *Journal of General Internal Medicine*. 2007;22(12):1695-1703.
307. Zukley LM. *The effects of a structured lifestyle intervention program in conjunction with dietary supplementation on weight loss and risk factors for the metabolic syndrome*. ProQuest Information & Learning; 2008.
308. Lundgren JD, Malcolm R, Binks M, O'Neil PM. Remission of metabolic syndrome following a 15-week low-calorie lifestyle change program for weight loss. *Int J Obes*. 2009;33(1):144-150.
309. Yalom ID, Leszcz M. *The theory and practice of group psychotherapy (5th ed.)*. New York, NY US: Basic Books; 2005.
310. Morrison N. GROUP COGNITIVE THERAPY: TREATMENT OF CHOICE OR SUB-OPTIMAL OPTION? *Behavioural and Cognitive Psychotherapy*. 2001;29(3):311-332.



311. Castelein SB. The effectiveness of peer support groups in psychosis: A randomized controlled trial. *Acta Psychiatr Scand.* 2008;118(1):64-72.
312. Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the united states, 2000. *JAMA: Journal of the American Medical Association.* 2004;291(10):1238-1245.
313. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. *JAMA: Journal of the American Medical Association.* 1999;282(16):1523-1529.
314. Saarni SE, Saarni SI, Fogelholm M, et al. Body composition in psychotic disorders: A general population survey. *Psychol Med.* 2009;39(05):801-810.
315. Reaven GM. Banting lecture 1988. role of insulin resistance in human disease. *Diabetes.* 1988;37(12):1595-1607.
316. Verweij KJH, Vinkhuyzen AAE, Benyamin B, et al. The genetic aetiology of cannabis use initiation: A meta-analysis of genome-wide association studies and a SNP-based heritability estimation. *Addict Biol.* 2013;18(5):846-850.
317. Palmer RHC, Button TM, Rhee SH, et al. Genetic etiology of the common liability to drug dependence: Evidence of common and specific mechanisms for DSM-IV dependence symptoms. *Drug Alcohol Depend.* 2012;123, Supplement 1:S24-S32.
318. Power RA, Verweij KJH, Zuhair M, et al. Genetic predisposition to schizophrenia associated with increased use of cannabis. *Mol Psychiatry.* 2014;19(11):1201-1204.
319. Starrenburg FCJ, Bogers JPAM. How can antipsychotics cause diabetes mellitus? insights based on receptor-binding profiles, humoral factors and transporter proteins. *European Psychiatry.* 2009;24(3):164-170.
320. Cohen T, Sundaresh S, Levine F. Antipsychotics activate the TGFbeta pathway effector SMAD3. *Mol Psychiatry.* 2013;18(3):347-357.
321. Herder C, Zierer A, Koenig W, Roden M, Meisinger C, Thorand B. Transforming growth factor-β1 and incident type 2 diabetes: Results from the MONICA/KORA case-cohort study, 1984–2002. *Diabetes Care.* 2009;32(10):1921-1923.
322. Lin Y, Nakachi K, Ito Y, et al. Variations in serum transforming growth factor-β1 levels with gender, age and lifestyle factors of healthy japanese adults. *Dis Markers.* 2009;27(1):23-28.
323. Azar ST, Salti I, Zantout MS, Major S. Alterations in plasma transforming growth factor β in normoalbuminuric type 1 and type 2 diabetic patients. *The Journal of Clinical Endocrinology & Metabolism.* 2000;85(12):4680-4682.
324. Fernandez-Egea E, Bernardo M, Donner T, et al. Metabolic profile of antipsychotic-naive individuals with non-affective psychosis. *The British Journal of Psychiatry.* 2009;194(5):434-438.

325. Ryan MCM, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naïve patients with schizophrenia. *Am J Psychiatry*. 2003;160(2):284-289.
326. Termorshuizen F, Wierdsma AI, Smeets HM, et al. Cause-specific mortality among patients with psychosis: Disentangling the effects of age and illness duration. *Psychosomatics*. 2013;54(6):536-545.
327. Thakore JH, Mann JN, Vlahos I, Martin A, Reznick R. Increased visceral fat distribution in drug-naïve and drug-free patients with schizophrenia. *International Journal of Obesity*. 2002;26(1):137-141.
328. Brochu PM, Esses VM. What's in a name? the effects of the labels fat versus overweight on weight bias. *J Appl Soc Psychol*. 2011;41(8):1981-2008.
329. Puhl RM, Heuer CA. The stigma of obesity: A review and update. *Obesity*. 2009;17(5):941-964.
330. Dickerson SS, Kemeny ME. Acute stressors and cortisol responses: A theoretical integration and synthesis of laboratory research. *Psychol Bull*. 2004;130(3):355-391.
331. Adam TC, Epel ES. Stress, eating and the reward system. *Physiol Behav*. 2007;91(4):449-458.
332. Muennig P. The body politic: The relationship between stigma and obesity-associated disease. *BMC Public Health*. 2008;8(1):1-10.
333. Grant PM, Beck AT. Defeatist beliefs as a mediator of cognitive impairment, negative symptoms, and functioning in schizophrenia. *Schizophrenia Bulletin*. 2009;35(4):798-806.
334. Staring ABP, Berg N. Cognitieve gedragstherapie voor patiënten met postpsychotische demoralisatie. *Directieve therapie*. 2012;30(4):280-302.
335. Inzlicht M, McKay L, Aronson J. Stigma as ego depletion: How being the target of prejudice affects self-control. *Psychological Science*. 2006;17(3):262-269.
336. Peet M. International variations in the outcome of schizophrenia and the prevalence of depression in relation to national dietary practices: An ecological analysis. *British Journal of Psychiatry*. 2004;184(5):404-408.
337. Peet M. Diet, diabetes and schizophrenia: Review and hypothesis. *British Journal of Psychiatry*. 2004;184(47):S102-S105.
338. Christensen O, Christensen E. Fat consumption and schizophrenia. *Acta Psychiatr Scand*. 1988;78(5):587-591.
339. Mellor JE, Laugharne JDE, Peet M. Omega-3 fatty acid supplementation in schizophrenic patients. *Hum Psychopharmacol Clin Exp*. 1996;11(1):39-46.
340. Roberts SH, Bailey JE. An ethnographic study of the incentives and barriers to lifestyle interventions for people with severe mental illness. *J Adv Nurs*. 2013;69(11):2514-2524.

341. Faulkner G, Sparkes A. Exercise as therapy for schizophrenia: An ethnographic study. *Journal of Sport & Exercise Psychology*. 1999;21:52-69.
342. Lee EHM, Hui CLM, Chang WC, et al. Impact of physical activity on functioning of patients with first-episode psychosis — A 6 months prospective longitudinal study. *Schizophr Res*. 2013;150(2–3):538-541.
343. Conus P, Lambert M, Cotton S, Bonsack C, McGorry PD, Schimmelmann BG. Rate and predictors of service disengagement in an epidemiological first-episode psychosis cohort. *Schizophr Res*. 2010;118(1–3):256-263.
344. Waterreus A, Di Prinzio P, Watts GF, Castle D, Galletly C, Morgan VA. Metabolic syndrome in people with a psychotic illness: Is cannabis protective? *Psychol Med*. 2016;First-View:1-12.
345. Jenkins DJA, Jones PJ, Frohlich J, et al. The effect of a dietary portfolio compared to a DASH-type diet on blood pressure. *Nutrition, Metabolism and Cardiovascular Diseases*. 2015;25(12):1132-1139.
346. Appel LJ, Sacks FM, Carey VJ, et al. Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids: Results of the omniheart randomized trial. *JAMA*. 2005;294(19):2455-2464.
347. Verhaeghe N, De Maeseneer J, Maes L, Van Heeringen C, Annemans L. Perceptions of mental health nurses and patients about health promotion in mental health care: A literature review. *J Psychiatr Ment Health Nurs*. 2011;18(6):487-492.
348. Casey D. Nurses' perceptions, understanding and experiences of health promotion. *J Clin Nurs*. 2007;16(6):1039-1049.
349. Happell B, Scott D, Platania-Phung C, Nankivell J. Should we or shouldn't we? mental health nurses' views on physical health care of mental health consumers. *International Journal of Mental Health Nursing*. 2012;21(3):202-210.
350. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. *Circulation*. 1998;97(18):1837-1847.
351. Van Alphen C, Ammeraal M, Blanke C, et al. *Multidisciplinaire richtlijn schizofrenie*. Utrecht: De Tijdstroom; 2012.
352. National Institute for Health and Care Excellence. Cardiovascular disease: Risk assessment and reduction, including lipid modification. NICE guideline (CG181). [www.nice.org.uk](http://www.nice.org.uk). Updated 2015.
353. Meeuwissen JAC, Hermens M, Van Gool R. Somatische screening bij patiënten met een ernstige psychische aandoening (EPA). [www.ggzrichtlijnen.nl](http://www.ggzrichtlijnen.nl). Updated 2014.
354. Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. *Am J Psychiatry*. 2004;161(8):1334-1349.
355. The Lancet Psychiatry. Psychiatrists with blinkers. *The Lancet*. 1979;314(8133):81.

356. Lamb H. Improving our public mental health systems. *Archives of General Psychiatry*. 1989;46(8):743-744.
357. Shore JH. Psychiatry at a crossroad: Our role in primary care. *Am J Psychiatry*. 1996;153(11):1398-1403.
358. Fleischhacker WW, Cetkovich-Bakmas M, De Hert M, et al. Comorbid somatic illnesses in patients with severe mental disorders: Clinical, policy, and research challenges. *Journal of Clinical Psychiatry*. 2008;69(4):514-519.
359. Boswell JF, Kraus DR, Miller SD, Lambert MJ. Implementing routine outcome monitoring in clinical practice: Benefits, challenges, and solutions. *Psychotherapy Research*. 2015;25(1):6-19.
360. Ministerie van Volksgezondheid, Welzijn en Sport. Bestuurlijk akkoord geestelijke gezondheidszorg 2014-2017. 112574-CZ. [www.rijksoverheid.nl](http://www.rijksoverheid.nl). Updated 2013.
361. Veldhuizen JR. FACT: A dutch version of ACT. *Community Ment Health J*. 2007;43(4):421-433.
362. Pirraglia PA, Rowland E, Wu W, et al. Benefits of a primary care clinic co-located and integrated in a mental health setting for veterans with serious mental illness. *Preventing Chronic Disease*. 2012;9:E51.
363. Viggiano T, Pincus HA, Crystal S. Care transition interventions in mental health. *Current Opinion in Psychiatry*. 2012;25(6).
364. Kocak FE, Ozturk B, Isiklar OO, Genc O, Unlu A, Altuntas I. A comparison between two different automated total 25-hydroxyvitamin D immunoassay methods using liquid chromatography-tandem mass spectrometry. *Biochemia Medica*. 2015;25(3):430-438.
365. Farrell CL, Martin S, McWhinney B, Straub I, Williams P, Herrmann M. State-of-the-art vitamin D assays: A comparison of automated immunoassays with liquid Chromatography–Tandem mass spectrometry methods. *Clinical Chemistry*. 2012;58(3):531-542.
366. Shephard RJ. Limits to the measurement of habitual physical activity by questionnaires. *British Journal of Sports Medicine*. 2003;37(3):197-206.
367. Madsen C, Fraser A. Supporting patients in shared decision making in clinical practice. *Nursing Standard*. 2015;29(31):50-57.
368. The Health Foundation. Helping people share decision making – A review of evidence considering whether shared decision making is worthwhile. . 2012.
369. Beitinger R, Kissling W, Hamann J. Trends and perspectives of shared decision-making in schizophrenia and related disorders. *Current Opinion in Psychiatry*. 2014;27(3).
370. Chong WW, Aslani P, Chen TF. Shared decision-making and interprofessional collaboration in mental healthcare: A qualitative study exploring perceptions of barriers and facilitators. - *Journal of Interprofessional Care*. 2013;27(5):373-379.

371. McCabe R, Khanom H, Bailey P, Priebe S. Shared decision-making in ongoing outpatient psychiatric treatment. *Patient Educ Couns*. 2013;91(3):326-328.
372. Fervaha G, Foussias G, Agid O, Remington G. Impact of primary negative symptoms on functional outcomes in schizophrenia. *European Psychiatry*. 2014;29(7):449-455.
373. Solbjør M, Rise MB, Westerlund H, Steinsbekk A. Patient participation in mental health-care: When is it difficult? A qualitative study of users and providers in a mental health hospital in Norway. *International Journal of Social Psychiatry*. 2013;59(2):107-113.
374. Sahlsten MJM, Larsson IE, Sjöström B, Plos KAE. Nurse strategies for optimising patient participation in nursing care. *Scand J Caring Sci*. 2009;23(3):490-497.
375. Hultsjö S, Hjelm K. Community health-care staff's experiences of support to prevent type 2 diabetes among people with psychosis: An interview study with health staff. *International Journal of Mental Health Nursing*. 2012;21(5):480-489.
376. Lisha NE, Sussman S. Relationship of high school and college sports participation with alcohol, tobacco, and illicit drug use: A review. *Addict Behav*. 2010;35(5):399-407.
377. Terry-McElrath YM, O'Malley PM. Substance use and exercise participation among young adults: Parallel trajectories in a national cohort-sequential study. *Addiction*. 2011;106(10):1855-1865.



